Protocols
7 protocol(s) meet the specified criteria
Disease Site: Any Site
Protocol No.TitleStatus
2843-1001A Phase I Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of MRX-2843 in Adult Subjects with Relapsed/Refractory Advanced and/or Metastatic Solid TumorsOpen
BP29889AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE IB STUDY WITH EXPANSION COHORTS TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND THERAPEUTIC ACTIVITY OF RO7009789 (CD40 AGONIST MONOCLONAL ANTIBODY) IN COMBINATION WITH VANUCIZUMAB (ANTI-ANG2 AND ANTI-VEGF BI-SPECIFIC MONOCLONAL ANTIBODY, PART I) OR BEVACIZUMAB (ANTI-VEGF MONOCLONAL ANTIBODY, PART II) IN PATIENTS WITH METASTATIC SOLID TUMORSOpen
EAY131-CIRBMolecular Analysis of Therapy Choice (MATCH)Open
FADOI03-2016Apixaban for the Treatment of Venous Thromboembolism in Patients with Cancer: a Prospective Randomized Open Blinded End-Point (PROBE) Study - The Caravaggio StudyOpen
LAO-NCI-9938-CIRBPhase I clinical trial of VX-970 in combination with the topoisomerase I inhibitor irinotecan in patients with advanced solid tumorsOpen
NCI-10057-CIRBA Phase II Study of Talimogene Iaherparepvec Followed by Talimogene Iaherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin TumorsOpen
NCI10061-CIRBA Phase 1 Study of Pembrolizumab (MK-3475) in Combination with Recombinant Interleukin-12 in Patients with Solid TumorsOpen